Dear Editor, Renal failure is a frequent complication of multiple myeloma (MM). Up to 50% of newly diagnosed patients present baseline renal dysfunction, and about 9% have renal failure requiring dialysis support [1] . More studies showed that dialysis should not represent an exclusion criteria from highdose chemotherapy and autologous stem cell transplant (ASCT) although a melphalan dose-reduction is suggested (100 mg/m 2 ) [2] [3] [4] . We report our experience in a small group of young patients with newly diagnosed MM requiring dialysis support for end-stage renal disease.
Five male patients were included in this report. All had newly diagnosis of symptomatic MM, end-stage renal disease, age under 65 years, performance status <3, and absence of cardiac or hepatic dysfunction (Table 1) .
Treatment plan included four VD (bortezomib and dexamethasone) cycles, stem cells mobilization and ASCT. Bortezomib was administrated after dialysis at the standard dose of 1.3 mg/m 2 on days 1, 4, 8, and 11 of a 21-day cycle. Dexamethasone was given at dose of 20 mg on the day of bortezomib and the day after. Stem cells were mobilized by cyclophosphamide 3 gr/m 2 and granulocytecolony-stimulating factor (G-CSF) priming. ASCT was conditioned with melphalan 100 mg/m 2 . The International Myeloma Working Group criteria were used for definition of response and toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute.
After VD cycles, all patients achieved a major response (two complete remission (CR) and three very good partial remission (VGPR)). Toxicity was mild, mainly consisting in fatigue (all cases), gastrointestinal symptoms (two cases), and grade 1-2 peripheral neuropathy (three cases). No patient reduced or discontinued bortezomib therapy. No recovery of renal function was documented, probably because of the interval between dialysis and diagnosis exceeding 1.5 months [5] .
Three of the five patients mobilized adequate numbers of stem cells (a median of 4.6×10 6 CD34/kg); one failed mobilization after two cycles (cyclophosphamide+G-CSF and G-CSF alone) and was withdrawn from the autograft program. One patient is still too early for the mobilization procedure. One month after mobilization, patients underwent to ASCT. A prompt and sustained engraftment was documented in all patients and the median number of days to reach 500 ANC/μl and 20,000 platelets/μl were 13 and 19, respectively. Chemotherapy was well-tolerated and toxicities were acceptable. All patients had febrile neutropenia and grade 2-3 mucositis. There was one episode of radiological documented fungal infection treated with voriconazol. No transplant-related deaths were observed. After the ASCT, two patients achieved a complete remission, one a near complete remission. After a median follow-up of 9 months (3-24), patients are alive and still in remission.
Our experience, although on a limited number of patients, confirm that ASCT with low dose of melphalan seems to be an attractive and feasible therapeutic option also for early MM patients in end-stage renal disease and show that bortezomib-based therapy as preparatory regimen before stem cell transplant is effective and well-tolerated.
Further randomized and prospective studies are warranted to evaluate safety and efficacy of this treatment plan and to identify a standard care in this setting.
